Výsledky vyhledávání - Stella, Peter
- Zobrazuji výsledky 1 - 14 z 14
-
1
-
2
-
3
Insulin Glargine 300 U/mL and Insulin Glulisine Treatment in Patients with Type 2 Diabetes: A Non-Interventional Study of Effectiveness in Routine Clinical Practice Autor Hidvégi, Tibor, Balogh, Zoltán, Vass, Viktor, Kovács, Gábor, Stella, Péter
Vydáno 2020Text -
4
Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study Autor Mathieu, Chantal, Weisnagel, S. John, Stella, Peter, Bruhwyler, Jacques, Alexandre, Kathy
Vydáno 2020Text -
5
Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis Autor Twigg, Stephen M., Escalada, Javier, Stella, Peter, Merino-Trigo, Ana, Lavalle-Gonzalez, Fernando J., Cariou, Bertrand, Meneghini, Luigi F.
Vydáno 2018Text -
6
-
7
Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA Autor Mauricio, Dídac, Meneghini, Luigi, Seufert, Jochen, Liao, Laura, Wang, Hongwei, Tong, Liyue, Cali, Anna, Stella, Peter, Carita, Paulo, Khunti, Kamlesh
Vydáno 2017Text -
8
Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-Worl... Autor Gupta, Shaloo, Wang, Hongwei, Skolnik, Neil, Tong, Liyue, Liebert, Ryan M., Lee, Lulu K., Stella, Peter, Cali, Anna, Preblick, Ronald
Vydáno 2018Text -
9
The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type... Autor Yale, Jean-François, Pettus, Jeremy Hodson, Brito-Sanfiel, Miguel, Lavalle-Gonzalez, Fernando, Merino-Trigo, Ana, Stella, Peter, Chevalier, Soazig, Buzzetti, Raffaella
Vydáno 2018Text -
10
Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score... Autor Tabák, Ádám G., Anderson, John, Aschner, Pablo, Liu, Minzhi, Saremi, Aramesh, Stella, Peter, Tinahones, Francisco J., Wysham, Carol, Meier, Juris J.
Vydáno 2019Text -
11
Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice‐daily basal insulin to once‐daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (ED... Autor Roussel, Ronan, d'Emden, Michael C., Fisher, Miles, Ampudia‐Blasco, F. Javier, Stella, Peter, Bizet, Florence, Cali, Anna M. G., Wysham, Carol H.
Vydáno 2017Text -
12
The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real‐world setting Autor Meneghini, Luigi F., Mauricio, Didac, Orsi, Emanuela, Lalic, Nebojsa M., Cali, Anna M.G., Westerbacka, Jukka, Stella, Peter, Candelas, DEA, Christophe, Pilorget, Valerie, Perfetti, Riccardo, Khunti, Kamlesh
Vydáno 2019Text -
13
Urinary NGAL Marks Cystic Disease in HIV-Associated Nephropathy Autor Paragas, Neal, Nickolas, Thomas L., Wyatt, Christina, Forster, Catherine S., Sise, Meghan, Morgello, Susan, Jagla, Bernd, Buchen, Charles, Stella, Peter, Sanna-Cherchi, Simone, Carnevali, Maria Luisa, Mattei, Silvia, Bovino, Achiropita, Argentiero, Lucia, Magnano, Andrea, Devarajan, Prasad, Schmidt-Ott, Kai M., Allegri, Landino, Klotman, Paul, D'Agati, Vivette, Gharavi, Ali G., Barasch, Jonathan
Vydáno 2009Text -
14
A validated, real-time prediction model for favorable outcomes in hospitalized COVID-19 patients Autor Razavian, Narges, Major, Vincent J., Sudarshan, Mukund, Burk-Rafel, Jesse, Stella, Peter, Randhawa, Hardev, Bilaloglu, Seda, Chen, Ji, Nguy, Vuthy, Wang, Walter, Zhang, Hao, Reinstein, Ilan, Kudlowitz, David, Zenger, Cameron, Cao, Meng, Zhang, Ruina, Dogra, Siddhant, Harish, Keerthi B., Bosworth, Brian, Francois, Fritz, Horwitz, Leora I., Ranganath, Rajesh, Austrian, Jonathan, Aphinyanaphongs, Yindalon
Vydáno 2020Text